Screener
Axsome Therapeutics AXSM Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Payment of contingent consideration | (3,262) | (2,285) |
| Payments of tax withholdings on stock awards | (9,301) | (4,336) |
| Net cash provided by financing activities | 2,994 | 29,270 |
| Net decrease in cash | (17,827) | (14,443) |
| Cash at beginning of period | 322,933 | 315,353 |
| Cash at end of period | $305,106 | $300,910 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $2,932 | $4,590 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's net change in cash?
- Axsome Therapeutics (AXSM) reported net change in cash of -$17.83M in Q1 2026.
- How has Axsome Therapeutics's net change in cash changed year-over-year?
- Axsome Therapeutics's net change in cash decreased by 23.4% year-over-year, from -$14.44M to -$17.83M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Axsome Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude